|
US7611713B2
(en)
|
1993-03-05 |
2009-11-03 |
Pharmexa Inc. |
Inducing cellular immune responses to hepatitis B virus using peptide compositions
|
|
US9340577B2
(en)
|
1992-08-07 |
2016-05-17 |
Epimmune Inc. |
HLA binding motifs and peptides and their uses
|
|
US7585622B1
(en)
|
1996-10-01 |
2009-09-08 |
Geron Corporation |
Increasing the proliferative capacity of cells using telomerase reverse transcriptase
|
|
US6183746B1
(en)
|
1997-10-09 |
2001-02-06 |
Zycos Inc. |
Immunogenic peptides from the HPV E7 protein
|
|
AU6465598A
(en)
*
|
1998-03-13 |
1999-09-27 |
Epimmune, Inc. |
Hla-binding peptides and their uses
|
|
WO2001024810A1
(en)
*
|
1999-10-05 |
2001-04-12 |
Epimmune Inc. |
Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
|
|
DE60020997T2
(de)
|
1999-12-06 |
2006-05-24 |
Hopital Sainte-Justine, Montreal |
Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose
|
|
US7462354B2
(en)
|
1999-12-28 |
2008-12-09 |
Pharmexa Inc. |
Method and system for optimizing minigenes and peptides encoded thereby
|
|
CN1452634A
(zh)
*
|
2000-02-23 |
2003-10-29 |
埃皮缪纳股份有限公司 |
Hla结合肽及其用途
|
|
CA2420225A1
(en)
*
|
2000-09-01 |
2002-03-14 |
Epimmune Inc. |
Hla-a2.1 binding peptides and their uses
|
|
US6974574B2
(en)
|
2001-08-16 |
2005-12-13 |
The General Hospital Corporation |
Methods of inducing an HIV specific response using a Vpr-specific epitope
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
AU2003286467B2
(en)
|
2002-10-15 |
2009-10-01 |
Abbvie Biotherapeutics Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
JP2007531707A
(ja)
|
2003-10-15 |
2007-11-08 |
ピーディーエル バイオファーマ， インコーポレイテッド |
ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
|
|
DE102005020911A1
(de)
*
|
2005-05-04 |
2006-11-16 |
Carl Zeiss Meditec Ag |
Verfahren zur Messung der Änderung des Polarisationszustands von polarisierter optischer Strahlung durch eine optisch aktive Schicht eines Körpers und/oder einer Konzentration eines optisch aktiven Stoffs in der Schicht und Vorrichtung zur Durchführung des Verfahrens
|
|
US8133691B2
(en)
|
2005-07-06 |
2012-03-13 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Stable quantitation and detection of immune response levels with non-zero background peptides
|
|
NZ582822A
(en)
*
|
2007-07-27 |
2012-06-29 |
Immatics Biotechnologies Gmbh |
Novel immunogenic epitopes for immunotherapy
|
|
WO2010086294A2
(en)
|
2009-01-28 |
2010-08-05 |
Epimmune Inc. |
Pan-dr binding polypeptides and uses thereof
|
|
CA2819416C
(en)
|
2010-12-02 |
2019-04-30 |
Bionor Immuno As |
Peptide scaffold design
|
|
MX346475B
(es)
|
2011-01-06 |
2017-03-22 |
Bionor Immuno As |
Peptidos inmunogenicos monomericos y multimericos.
|
|
US10501499B2
(en)
|
2012-06-06 |
2019-12-10 |
Bionor Immuno As |
Peptides derived from viral proteins for use as immunogens and dosage reactants
|
|
EP2745845A1
(en)
|
2012-12-19 |
2014-06-25 |
Centre Hospitalier Universitaire de Bordeaux |
A method for preventing or treating an HIV infection
|
|
CN105200010B
(zh)
*
|
2015-10-15 |
2019-02-12 |
首都医科大学附属北京佑安医院 |
艾滋病感染者hla-a2特异性ctl细胞的体外培养方法及其专用培养基
|